Ardelyx Secures Extended Patent for Tenapanor, Expires 2042

Event summary

  • Ardelyx received a new patent (No. 12,539,299) for tenapanor formulations, extending protection until November 26, 2042.
  • The patent covers commercial formulations of IBSRELA® and XPHOZAH®, both tenapanor-based therapies.
  • The expiration date was adjusted due to USPTO delays, reflecting a Patent Term Adjustment.
  • Ardelyx plans to submit the patent for listing in the FDA’s Orange Book.

The big picture

Ardelyx’s new patent for tenapanor formulations extends its competitive moat in the gastrointestinal and chronic kidney disease markets. The extended protection until 2042 provides strategic flexibility for commercialization and potential partnerships. The biopharmaceutical industry continues to prioritize intellectual property as a key differentiator, particularly in therapeutic areas with significant unmet needs.

What we're watching

Patent Strategy
Whether Ardelyx can leverage this extended patent protection to strengthen its market position in IBS-C and CKD treatments.
Commercialization Efforts
The pace at which Ardelyx can expand the commercial reach of IBSRELA and XPHOZAH, particularly through its international partnerships.
Pipeline Development
How the patent extension impacts Ardelyx’s ability to invest in and advance its pipeline, including RDX10531.